1. A Question of Adoption: Strategies and Best Practice for Adoption of Medical Technology How to maximize medical technology adoption by involving the right people at the right time throughout the product development process Jeffrey R. Scott, Ph.D. Principal Scientist Preclinical Affairs C.R. Bard, Inc. (Davol) jeffrey.scott@crbard.com

4. Area of Business/Research Focus

5. Rapid Innovation / Adoption

6. Surgeon Involvement During Product Development

8. A publicly traded company – BCR

9. Market Cap: $9.3B, Annual Revenue of $2.8B

10. 11,700 employees worldwide

11. Headquartered in Murray Hill, NJ

12. 5 divisions - RI, Massachusetts, Georgia, Utah, Arizona

13. Vascular, Urology, Oncology, Surgical Specialties

14. Global presence Europe, Japan, Canada, Australia, Latin America, Asia, China

15. Davol, Inc. History Joseph Davol Charles Davol

16. Davol, Inc. History 1874: Davol Rubber Company founded to produce rubber medical and surgical supplies such as hot water bottles and catheters. 1923: C. R. Bard, Inc. is exclusive Davol Foley catheter distributor 1968: Davol, Inc. acquired by International Paper, Inc. 1971: Davol, Inc. headquarters moved from Providence to Cranston, RI. 1980: Acquired by C. R. Bard, Inc. from International Paper, Inc. for $48MM. Single largest selling product was the Foley catheter manufactured by Davol, Inc. 2008: Company moved from Cranston, RI to new division headquarters in Warwick, RI.

18. Broadest/deepest product line in the industry

19. Portfolio of patented, proprietary products

20. Highly trained, professional sales team - surgeon consultants

21. Innovative Marketing Programs

22. Surgeon training

24. Area of Business/Research Focus

25. Rapid Innovation / Adoption

26. Surgeon InvolvementDuring Product Development

28. Soft Tissue Reconstruction – Hernia Repair

29. Soft Tissue Reconstruction – Breast Reconstruction

31. Area of Business/Research Focus

32. Rapid Innovation / Adoption

33. Surgeon InvolvementDuring Product Development

35. Synthetic Inguinal Products 3DMax™ Mesh PerFix™Plug Bard® Soft Mesh MK™Patch Kugel™Patch

36. Synthetic Ventral & Specialty Products Composix™ EX Mesh Ventralex™ Patch Ventrio™ Patch CruraSoft™ Hiatal Patch Composix™ L/P Mesh Sepramesh™ IP CK™ Parastomal Patch

37. Mesh Fixation SorbaFix™ Absorbable Fixation Device PermaSorb™ Absorbable Fixation Device

38. Biologically-derived Implants CollaMend™ FM Implant AlloMax™ Surgical Graft XenMatrix™ Surgical Graft

40. Area of Business/Research Focus

41. Rapid Innovation / Adoption

42. Surgeon InvolvementDuring Product Development

44. Where does innovation happen? Office

45. Where does innovation happen? Lab

46. Where does innovation happen? O.R.

47. Where does innovation happen? What is the impact on adoption? Office O.R. Lab Better Products & Rapid Adoption

48. Animal Models Developed in vivo: Open / Laparoscopic Ventral Hernia Repair Rat:Long-term Material Characterization / Adhesion Assessment / Infection Rabbit: Mid-term Material Characterization / Adhesion Assessment / Infection Pig: Short-term (Clinically-Relevant) Material / Adhesion Assessment Mini-Pig: Long-term (Clinically-Relevant) Material / Adhesion Assessment ex vivo: Hernia Repair Assessment PAW: Mechanical Assessment: Fixation, Burst; Laparoscopic Insertion

49. Animal Models Developed - Laparoscopic

50. Animal Models Developed - Open

51. Animal Models Developed – Breast Reconstruction

54. Area of Business/Research Focus

55. Rapid Innovation

56. Surgeon InvolvementDuring Product Development

58. Products are Safer and More Effective

59. Maximize Return on Research Investment

60. Strong Podium Presence at Launch

61. Surgeon EducationRapid Product Adoption

62. A Question of Adoption: Strategies and Best Practice for Adoption of Medical Technology How to maximize medical technology adoption by involving the right people throughout the product development process Jeffrey R. Scott, Ph.D. Principal Scientist Preclinical Affairs C.R. Bard, Inc. (Davol) jeffrey.scott@crbard.com